The Partnership to Fight Infectious Disease (PFID) is a group of patients, providers, community organizations, academic researchers, business and labor groups, and infectious disease experts working to raise awareness of threats posed by infectious disease. As an initiative of the Partnership to Fight Chronic Disease, PFID will explore and advance solutions to address the need to enhance pandemic preparedness, address the growing threat of antimicrobial resistance and the need for new antimicrobial treatments; and empower informed choice and confidence in COVID-19 vaccines.
The COVID-19 crisis has reinforced the critical importance of treatments for infectious diseases. Ultimately, the development, availability, and adoption of safe and effective vaccines for COVID-19 are the quickest, safest way to control COVID-19 and enable normal activities to resume. We also need new antibiotics and anti fungal medicines to treat the serious bacterial infections that can cause pneumonia or other complications related to COVID-19 illness. Our supply of effective antibiotics, however, is shrinking due to the growth of antimicrobial resistance (AMR).